Merrill Lynch analyst Tazeen Ahmad reiterated a Buy rating on GW Pharma (NASDAQ:GWPH) on Monday, setting a price target of $234, which is approximately 82.51% above the present share price of $128.21.
Ahmad expects GW Pharma to post earnings per share (EPS) of $0.00 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in GW Pharma, with an average price target of $165.56.
The analysts price targets range from a high of $234 to a low of $121.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $137.05 million and a net profit of -$12.72 million. The company's market cap is $4 billion.
According to TipRanks.com, Merrill Lynch analyst Tazeen Ahmad is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.6% and a 56.82% success rate.
GW Pharmaceuticals (OTC:GWPRF) Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.